Study: New drug prevents cytomegalovirus in stem cell transplant patients

09/25/2013 | Medscape (free registration)

A new oral antiviral drug that contains cidofovir proved effective in preventing cytomegalovirus infection in patients who had allogeneic hematopoietic cell transplants. A Phase II study published in the New England Journal of Medicine found that 10% of patients treated with CMX001 reported CMV incidence, compared with 37% in a placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC